FML® suspension is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.

Shake well before using. Instill one drop into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased to one application every four hours. Care should be taken not to discontinue therapy prematurely.

If signs and symptoms fail to improve after two days, the patient should be re-evaluated (see PRECAUTIONS).

The dosing of FML® suspension may be reduced, but care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of applications.

FML® (fluorometholone ophthalmic suspension, USP) 0.1% is supplied sterile in opaque white LDPE plastic bottles with white high impact polystyrene (HIPS) caps as follows:

5 mL in 10 mL bottle - NDC 11980-211-05
10 mL in 15 mL bottle - NDC 11980-211-10
15 mL in 15 mL bottle - NDC 11980-211-15

Storage

Store at 2° - 25°C (36°-77°F); protect from freezing. Store in an upright position.

Irvine, CA 92612, U.S.A. ® marks owned by Allergan, Inc. Made in the U.S.A. Revised: 02/2013

Last reviewed on RxList: 3/12/2013
This monograph has been modified to include the generic and brand name in many instances.